ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Gastrointestinal Stromal Tumor (GIST) Report 2016 - Pipeline Review of 23 Pharma Companies & Drug Profiles - Research and Markets
ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients
ARIAD to Present at the Jefferies 2016 Global Healthcare Conference
ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations
These two small-value funds have followed different paths to success in a difficult year for the peer group.